Pharmaxis announced it has appointed Dr. Kathleen Metters to the Board of Directors. Dr. Metters has more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases. Dr. Metters spent 9 years as a senior executive with Merck & Co. (Merck Sharp & Dohme (MSD) outside the United States and Canada) which included a 4 year period as senior vice president and head of Worldwide Basic Research. Dr. Metters will serve as a Non Executive Director on the Pharmaxis Board - joining current members Malcolm McComas, Simon Buckingham, Will Delaat and Gary Phillips.